BR112023023151A2 - Formulações líquidas iônicas para tratamento de doenças inflamatórias e autoimunes - Google Patents
Formulações líquidas iônicas para tratamento de doenças inflamatórias e autoimunesInfo
- Publication number
- BR112023023151A2 BR112023023151A2 BR112023023151A BR112023023151A BR112023023151A2 BR 112023023151 A2 BR112023023151 A2 BR 112023023151A2 BR 112023023151 A BR112023023151 A BR 112023023151A BR 112023023151 A BR112023023151 A BR 112023023151A BR 112023023151 A2 BR112023023151 A2 BR 112023023151A2
- Authority
- BR
- Brazil
- Prior art keywords
- ionic liquid
- inflammatory
- autoimmune diseases
- liquid formulations
- treatment
- Prior art date
Links
- 239000002608 ionic liquid Substances 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 208000023275 Autoimmune disease Diseases 0.000 title abstract 3
- 208000027866 inflammatory disease Diseases 0.000 title abstract 3
- 230000002757 inflammatory effect Effects 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 abstract 2
- 150000001450 anions Chemical class 0.000 abstract 1
- 150000001768 cations Chemical class 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 abstract 1
- 229960001231 choline Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
formulações líquidas iônicas para tratamento de doenças inflamatórias e autoimunes. a presente divulgação fornece composições compreendendo um agente terapêutico e pelo menos um líquido iônico e uso das mesmas para tratar condições ou doenças em um indivíduo. especificamente, a presente divulgação fornece um método de tratamento de doenças inflamatórias e autoimunes através da dispensação de formulações líquidas iônicas compreendendo colina como cátion e vários ânions; e um anticorpo terapêutico ou um reagente de anticorpo para um indivíduo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163184333P | 2021-05-05 | 2021-05-05 | |
| PCT/US2022/027794 WO2022235882A1 (en) | 2021-05-05 | 2022-05-05 | Ionic liquid formulations for treating inflammatory and autoimmune diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023023151A2 true BR112023023151A2 (pt) | 2024-01-23 |
Family
ID=83932928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023023151A BR112023023151A2 (pt) | 2021-05-05 | 2022-05-05 | Formulações líquidas iônicas para tratamento de doenças inflamatórias e autoimunes |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240067716A1 (pt) |
| EP (1) | EP4333891A1 (pt) |
| JP (1) | JP2024518169A (pt) |
| KR (1) | KR20240046687A (pt) |
| CN (1) | CN117642180A (pt) |
| AU (1) | AU2022270665A1 (pt) |
| BR (1) | BR112023023151A2 (pt) |
| CA (1) | CA3217942A1 (pt) |
| IL (1) | IL308290A (pt) |
| MX (1) | MX2023013070A (pt) |
| WO (1) | WO2022235882A1 (pt) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2946765B1 (en) * | 2014-05-23 | 2016-08-31 | Ares Trading S.A. | Liquid pharmaceutical composition |
| US10463733B1 (en) * | 2016-10-04 | 2019-11-05 | United States of America as represented by the Secetary of the Air Force | Ultra-stable protein ionic liquids |
| US11608357B2 (en) * | 2018-08-28 | 2023-03-21 | Arecor Limited | Stabilized antibody protein solutions |
| WO2020004368A1 (ja) * | 2018-06-25 | 2020-01-02 | Ｊｃｒファーマ株式会社 | 蛋白質含有水性液剤 |
| US20220144914A1 (en) * | 2019-03-01 | 2022-05-12 | President And Fellows Of Harvard College | Methods and compositions for protein delivery |
-
2022
- 2022-05-05 MX MX2023013070A patent/MX2023013070A/es unknown
- 2022-05-05 CA CA3217942A patent/CA3217942A1/en active Pending
- 2022-05-05 BR BR112023023151A patent/BR112023023151A2/pt unknown
- 2022-05-05 CN CN202280048159.3A patent/CN117642180A/zh active Pending
- 2022-05-05 AU AU2022270665A patent/AU2022270665A1/en active Pending
- 2022-05-05 EP EP22799564.4A patent/EP4333891A1/en active Pending
- 2022-05-05 JP JP2023568524A patent/JP2024518169A/ja active Pending
- 2022-05-05 KR KR1020237041826A patent/KR20240046687A/ko unknown
- 2022-05-05 WO PCT/US2022/027794 patent/WO2022235882A1/en active Application Filing
- 2022-05-05 IL IL308290A patent/IL308290A/en unknown
-
2023
- 2023-11-03 US US18/501,735 patent/US20240067716A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024518169A (ja) | 2024-04-25 |
| CN117642180A (zh) | 2024-03-01 |
| KR20240046687A (ko) | 2024-04-09 |
| WO2022235882A1 (en) | 2022-11-10 |
| IL308290A (en) | 2024-01-01 |
| US20240067716A1 (en) | 2024-02-29 |
| CA3217942A1 (en) | 2022-11-10 |
| AU2022270665A1 (en) | 2023-12-07 |
| EP4333891A1 (en) | 2024-03-13 |
| MX2023013070A (es) | 2024-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022002150A2 (pt) | Composições e métodos para tratar psoríase e dermatite atópica com o uso de prevotella histicola | |
| BR112017023380A2 (pt) | sistema, composição cosmética, métodos para tratamento de substratos queratinosos e para proteção e/ou alisamento da fibra do cabelo, kit multicompartimento, e, processo para alisamento do cabelo. | |
| CA3006294A1 (en) | Combinations of rapamycin and metformin for the treatment of joint and skin diseases | |
| BR112017007975A2 (pt) | composições e métodos para o tratamento de disfunção das glândulas meibomianas | |
| BR112013018920A2 (pt) | composições de nanopartículas, formulações destas e seus usos | |
| BR112014028633A8 (pt) | tratamento de amd usando sflt-1 de aav | |
| BR112015000776A2 (pt) | Agentes de ligação à rspo3 e usos dos mesmos | |
| BR112015021392A2 (pt) | uso de agonistas do receptor de peptídeo formil 2 para tratar doenças dermatológicas | |
| BR112016022318A2 (pt) | método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo | |
| BR112014014783A2 (pt) | moléculas de inibidor de jnk para tratamento de várias doenças | |
| BR112016018205A8 (pt) | métodos de tratamento de mal de alzheimer, de seleção de pacientes, de identificação de pacientes, de previsão, de otimização da eficácia terapêutica, kit, uso de agente e uso in vitro de agente | |
| BR112016003381A8 (pt) | sistema para administrar uma formulação de cantaridina a um indivíduo; dispositivo aplicador para administrar uma formulação de cantaridina a um indivíduo; usos de uma formulação de cantaridina; kit para administrar uma formulação de cantaridina a um indivíduo; formulações; e formulação de cantaridina | |
| BR112018013063A2 (pt) | combinação terapêutica inibidora de bromodomínio e proteína extra-terminal | |
| BR112018014467A2 (pt) | tecnologia de sinergismo fármaco-anticorpo para o tratamento de doenças | |
| BR112019006880A2 (pt) | compostos e composições para tratamento de leishmaniose e métodos de diagnóstico e tratamen-to usando os mesmos | |
| BR112021025732A2 (pt) | Inibidores macrocíclicos de mcl-1 | |
| BRPI0511398A (pt) | composição farmacêutica anidra para o tratamento da psorìase e uso de um agente siliconado | |
| BR112014010594A2 (pt) | terapia genética para neuropatia diabética empregando um isoforma do hgf | |
| CO2022013055A2 (es) | Tafoxiparina para el tratamiento de la preeclampsia | |
| BR112019006174A2 (pt) | proteina terapêutica | |
| BR112021018918A2 (pt) | Compostos e composições como moduladores de sinalização de tlr | |
| BR112021017957A2 (pt) | Derivado tienoeterocíclico, método de preparação do mesmo e uso médico do mesmo | |
| BR112023023151A2 (pt) | Formulações líquidas iônicas para tratamento de doenças inflamatórias e autoimunes | |
| Kaewsrisung et al. | The effects of oral Aloe vera on the efficacy of transplanted human endothelial cells and the expression of matrix metalloproteinases in diabetic wound healing | |
| BR112022001700A2 (pt) | Método para tratar doença de alzheimer regulando-se o nível de aminoácidos |